274 related articles for article (PubMed ID: 33984191)
21. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.
Beyer J; Trujillo T; Fisher S; Ko A; Lind SE; Kiser TH
Clin Appl Thromb Hemost; 2016 Jul; 22(5):423-8. PubMed ID: 26842561
[TBL] [Abstract][Full Text] [Related]
22. First evidence: rivaroxaban and apixaban reduce thrombin-dependent platelet aggregation.
Sokol J; Nehaj F; Ivankova J; Mokan M; Mokan M
J Thromb Thrombolysis; 2018 Oct; 46(3):393-398. PubMed ID: 30039454
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban.
Bookstaver DA; Sparks K; Pybus BS; Davis DK; Marcsisin SR; Sousa JC
Ann Pharmacother; 2018 Mar; 52(3):251-256. PubMed ID: 29047306
[TBL] [Abstract][Full Text] [Related]
24. Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation.
Semeraro F; Incampo F; Ammollo CT; Dellanoce C; Paoletti O; Testa S; Colucci M
Thromb Res; 2016 Feb; 138():22-29. PubMed ID: 26826504
[TBL] [Abstract][Full Text] [Related]
25. [Large studies of NOAC shows good and safe stroke protection].
Hijazi Z; Oldgren J
Lakartidningen; 2015 Sep; 112():. PubMed ID: 26348046
[No Abstract] [Full Text] [Related]
26. Platelet Aggregation in Direct Oral Factor Xa Inhibitors-treated Patients With Atrial Fibrillation: A Pilot Study.
Bánovčin P; Škorňová I; Samoš M; Schnierer M; Bolek T; Kovář F; Staško J; Kubisz P; Mokáň M
J Cardiovasc Pharmacol; 2017 Oct; 70(4):263-266. PubMed ID: 28708713
[TBL] [Abstract][Full Text] [Related]
27. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Schneeweiss S; Gagne JJ; Patrick AR; Choudhry NK; Avorn J
Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):480-6. PubMed ID: 22787066
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
[TBL] [Abstract][Full Text] [Related]
29. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
Amin A; Keshishian A; Dina O; Dhamane A; Nadkarni A; Carda E; Russ C; Rosenblatt L; Mardekian J; Yuce H; Baker CL
J Thromb Thrombolysis; 2019 Aug; 48(2):240-249. PubMed ID: 30924051
[TBL] [Abstract][Full Text] [Related]
30. Safety of apixaban and rivaroxaban in patients with atrial fibrillation on hemodialysis.
Ito H
Eur J Intern Med; 2024 Jun; 124():154-155. PubMed ID: 38342714
[No Abstract] [Full Text] [Related]
31. Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation.
Horinaka S; Sugawara R; Yonezawa Y; Ishimitsu T
Br J Clin Pharmacol; 2018 Jan; 84(1):79-87. PubMed ID: 28888219
[TBL] [Abstract][Full Text] [Related]
32. Is transesophageal echocardiogram mandatory in patients undergoing ablation of atrial fibrillation with uninterrupted novel oral anticoagulants? Results from a prospective multicenter registry.
Di Biase L; Briceno DF; Trivedi C; Mohanty S; Gianni C; Burkhardt JD; Mohanty P; Bai R; Gunda S; Horton R; Bailey S; Sanchez JE; Al-Ahmad A; Hranitzky P; Gallinghouse GJ; Reddy YM; Zagrodzky J; Hongo R; Beheiry S; Lakkireddy D; Natale A
Heart Rhythm; 2016 Jun; 13(6):1197-202. PubMed ID: 26994940
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
[TBL] [Abstract][Full Text] [Related]
34. [Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].
Meddahi S; Samama MM
J Mal Vasc; 2014 May; 39(3):183-94. PubMed ID: 24650612
[TBL] [Abstract][Full Text] [Related]
35. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
36. Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarin.
Farr AM; Jing Y; Johnston S; Trocio J; Singhal S; Bruno A; Graham J
Hosp Pract (1995); 2015; 43(3):172-9. PubMed ID: 26213178
[TBL] [Abstract][Full Text] [Related]
37. Low molecular weight heparin anti-Xa assays can identify patients with clinically important apixaban and rivaroxaban drug levels.
Mithoowani S; Moffat KA; Gupta A; Carlino SA; Crowther MA
Thromb Res; 2022 Jul; 215():1-4. PubMed ID: 35580465
[No Abstract] [Full Text] [Related]
38. Shorter hospital stays in epistaxis patients with atrial fibrillation when taking rivaroxaban or apixaban versus phenprocoumon.
Stankovic P; Georgiew R; Frommelt C; Hammel S; Wittlinger J; Hoch S; Obradovic D; Dagres N; Wilhelm T
J Thromb Thrombolysis; 2019 Apr; 47(3):384-391. PubMed ID: 30729376
[TBL] [Abstract][Full Text] [Related]
39. Laboratory measurement of apixaban using anti-factor Xa assays in acute ischemic stroke patients with non-valvular atrial fibrillation.
Shin H; Cho MC; Kim RB; Kim CH; Choi NC; Kim SK; Koh EH
J Thromb Thrombolysis; 2018 Feb; 45(2):250-256. PubMed ID: 29198080
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
